

# APPLICATION UNDER UNITED STATES PATENT LAWS

Atty. Dkt. No. PW 279329  
(M#)

Invention: TREATMENT OF SUBSTANCE P-RELATED DISORDERS

Inventor (s): Eric GROUZMANN  
Jean-Silvain LACROIX  
Michel MONOD

Pillsbury Winthrop LLP  
Intellectual Property Group  
1600 Tysons Boulevard

McLean, VA 22102  
Attorneys  
Telephone: (703) 905-2000

This is a:

- ☐ Provisional Application
- ☒ Regular Utility Application
- ☐ Continuing Application
  - ☒ The contents of the parent are incorporated by reference
- ☐ PCT National Phase Application
- ☐ Design Application
- ☐ Reissue Application
- ☐ Plant Application
- ☐ Substitute Specification
  - Sub. Spec. Filed \_\_\_\_\_
  - in App. No. \_\_\_\_\_ / \_\_\_\_\_
- ☐ Marked up Specification re
  - Sub. Spec. filed \_\_\_\_\_
  - In App. No. \_\_\_\_\_ / \_\_\_\_\_

## SPECIFICATION

## Treatment of Substance P-Related Disorders

### Field of the Invention

The present invention is directed to methods of treating a variety of diseases, disorders and conditions using agents that, effectively, serve as substance P antagonists. The agents are peptidases that selectively cleave at Xaa-Pro amino acid residues.

### Background of the Invention

Substance P is a peptide 11 amino acids in length and is a member of the tachykinin family (see U.S. 4,680,283). It is a neurotransmitter that is released by nerve endings in both the central and peripheral nervous systems. Among the numerous biological sites innervated by substance P-releasing neurons are the skin, intestines, stomach, bladder and cardiovascular system (see U.S. 6,146,636).

Because of its wide distribution, a very large and varied group of disorders have been associated with excessive production of substance P. In particular, substance P has been reported to be involved in the transmission of pain (particularly pain associated with migraine headache), in arthritis, in gastrointestinal disorders, and in emesis (Otsuka, *et al.*, *Ciba Foundation Symp* 91:13-34 (1982); Otsuka, *et al.*, *Tips* 8:506-510 (1987); Sandberg, *et al.*, *J. Med. Chem.* 25:1009 (1982); Levine, *et al.*, *Science* 226:547-549 (1984); Mantyh, *et al.*, *Neurosci.* 25:817-837 (1988); Tattersall, *et al.*, *Eur. J. Pharmacol.* 250:R5-R6 (1993); Gronblad, *et al.*, *J. Rheumatol.* 15:1807-1810 (1988)). Excessive levels of substance P are also believed to contribute to allergic conditions, vasospastic conditions, neurodegenerative disorders and immunological disorders (Hamelet, *et al.*, *Can. J. Pharmacol. Physiol.* 66:1361-1367 (1988); Lotz, *et al.*, *Science* 241:1218-1221 (1988); Kimball, *et al.*, *Immunol.* 141:3464-3569 (1988); Mantyh, *et al.*, *Proc. Nat'l Acad Sci. USA* 85:3235-3239 (1988); Yankner, *et al.*, *Science* 250:279-282 (1990)).

There have also been reports suggesting that substance P may contribute to certain types of cancer, to autoimmune diseases and to disorders of bladder function (Langdon, *et al.*, *Cancer Res.* 52:4554-4557 (1992); EP 436 334; Luber-Narod, *et al.*, *Lancet* pg. 1239, May 16, 1992). Finally, there are suggestions in the literature that abnormal substance P levels are associated with arthritic diseases, dysthymic disorders, urinary disorders, collagen-related

diseases, ophthalmic diseases, drug withdrawal syndromes and certain CNS disorders such as psychoses and schizophrenia (EP 394 989; EP 436,334; Maggi, *et al. J. Auton. Pharmacol.* 13:23-93 (1993)).

5        Given the extremely broad array of pathologies that substance P has been found to contribute in, it is not surprising that many different substance P antagonists have been developed and tested in the treatment of diseases and conditions. Among the numerous reports that have appeared in the literature discussing such antagonists are the following: U.S. 6,146,636; U.S. 4,472,305; U.S. 4,839,465; EP 499313; EP 522808; WO 93/01165; WO  
10    93/09116; EP 514274; and WO 93/01169. Many of the approaches taken to antagonizing P activity have focused upon agents that bind to and block receptors for this peptide. However, other approaches may be taken to antagonizing substance P activity and these may contribute to the treatment of all of the diseases and conditions described above.

#### 15    **Summary of the Invention**

      The present invention is based upon the concept that peptidases that cleave selectively at Xaa-Pro amino acid residues may be administered to patients as a treatment for diseases, disorders and conditions associated with abnormally elevated levels of substance P. The peptidases cleave the first, 2 to 4 residues of substance P thereby producing a peptide,  
20    substance P 5-11 that can no longer effectively bind to and activate receptor. Thus, the peptidases act essentially as "antagonists" by reducing the available levels of intact peptide ligand. They may be administered either systemically or locally for the treatment of any of the disorders reported in the literature as being amenable to treatment with substance P antagonists.

25        In its broadest aspect, the present invention is directed to a method of treating a patient for a substance P-related disease, disorder or condition (collectively "malady") in which a therapeutically effective amount of a peptidase that cleaves selectively at Xaa-Pro sequences is administered. The term "therapeutically effective amount" is a dosage sufficient  
30    to produce a significant reduction in one or more symptoms associated with the disease or disorder being treated. For example, in the treatment of conditions such as migraine headache, neuropathic pain, arthritis and inflammatory conditions, a therapeutically effective amount would be a dosage sufficient to reduce the amount of pain or discomfort experienced

by the patient. Similarly, a therapeutically effective amount would be a dosage sufficient to reduce the excessive motility associated with conditions such as irritable bowel syndrome or to reduce the rate of tumor growth in small cell carcinoma of the lung. The substance P-related maladies that may be treated are selected from the group consisting of CNS disorders; addiction withdrawal; neuropathic pain; postherpetic pain; neurodegenerative disorders; autoimmune diseases; disorders of the gastrointestinal tract; vasospastic diseases, skin disorders; collagen-related disorders; cardiovascular diseases and conditions; urinary tract disorders; arthritic diseases; ophthalmic diseases; cancer; oedema; emesis; dysthymic disorders; and reflex sympathetic dystrophy.

Preferred maladies amenable to the present treatment method include the following:

- a) CNS disorders such as psychosis, anxiety and depression;
- b) addiction withdrawal from alcohol or a narcotic;
- c) neuropathic pain or postherpetic pain;
- d) neurodegenerative maladies such as Alzheimer's disease; AIDS-related dementia, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome;
- e) autoimmune diseases such as systemic lupus erythmatosus and multiple sclerosis;
- f) disorders of the gastrointestinal tract such as colitis, Crohn's disease and irritable bowel syndrome;
- g) vasospastic diseases such as migraine headache, Reynaud's disease and angina;
- h) disorders or conditions of the skin such as sunburn, psoriasis, dermatitis, uticaria, and inflammation (*e.g.*, due to exposure to poison ivy);
- i) collagen-related disorders such as fibrositis, scleroderma, and eosinophilic fascioliasis;
- j) hypertension or other cardiovascular diseases and conditions;
- k) urinary tract disorders such as incontinence, cystitis, bladder hyper-reflexia, and bladder hypermotility;
- l) arthritic diseases such as rheumatoid arthritis and osteoarthritis;

- m) ophthalmic diseases or conditions such as proliferative vitreoretinopathy, ocular injury and conjunctivitis;
- n) small cell carcinoma of the lung and other cancers; and
- o) oedema, emesis, dysthymic disorders and reflex sympathetic dystrophy.

As discussed above, the present treatment method involves the administration of a peptidase that cleaves selectively at Xaa-Pro residues. Xaa represents any of the 20 amino acids commonly found in the proteins of animals. The term "selectively cleaves" indicates that the peptidase acts at essentially only these sites in peptides. Preferably, the method utilizes exopeptidases selected from dipeptidyl peptidase IV, quiescent cell proline dipeptidase, dipeptidyl peptidase 8 and attractin. In each case, it is the human form of the peptidase that is preferred. However, peptidases from other species, (e.g., those secreted by *Aspergillus fumigatus*) may also be used provided they have the required specificity. In all cases, it is expected that a therapeutically effective dose for any of the peptidases will be between 1 microgram and 1 milligram. Typically, between 5 micrograms and 500 micrograms will be used.

### Brief Description of the Drawings

Figure 1: Figure 1 shows changes in percent airway resistance induced by aerosolized histamine (2 mg) in an anesthetized rabbit. Changes were measured before and after the administration of DPP IV (0.1 mg) nebulisation (n=4). Paired t-test, \* p<0.05.

Figure 2: Figure 2 shows the reduction of vascular resistance in the femoral artery of an anesthetized rabbit, induced by histamine, before (darker bar) and after systemic intravenous pretreatment with 26.5 pmol/kg DPP IV (n=5). Paired t test, \* p<0.05.

Figure 3: Figure 3 shows the reduction in vascular resistance in the femoral artery of an anesthetized rabbit, induced by the administration of substance P, before (darker bars) and after systemic intravenous pretreatment with 26.5 pommels/kg DPP IV (n=10). ANOVA, post test: Toukai, \* p<0.05, \*\* p<0.01; \*\*\* p<0.001.

## Detailed Description of the Invention

### A. Preparation of Peptidases

The present invention is directed to treatment methods which utilize peptidases that have the common characteristic of cleaving selectively at Xaa-Pro sites. These may be purchased commercially or obtained using any of the procedures described in the relevant literature. For example, the gene corresponding to the peptidase can be isolated and used for recombinant protein production. Especially preferred peptidases, along with references relevant to their isolation and recombinant production, are: human dipeptidyl peptidase IV (Misumi, *et al.*, *Biochim. Biophys. Acta* 15:1131 (1992); Darmoul, *et al.*, *J. Biol. Chem.* 267:4824-4833 (1992); Abbott, *et al.*, *Immunogenetics* 40:331-338 (1994)); human quiescent cell proline dipeptidase (Underwood, *et al.*, *J. Biol. Chem.* 274:34053-34058 (1999)); human attractin (Duke-Cohan, *et al.*, *Proc. Nat'l. Acad. Sci. USA* 95:11336-11341 (1998); Nagase, *et al.*, *DNA Res.* 5:31-39 (1998)); and human dipeptidyl peptidase 8 (Abbott, *et al.*, *Eur. J. Biochem.* 267:6140-6150 (2000)). In addition to being made recombinantly, these proteins can be synthesized using methods that are well-known in the art.

### B. Making of Pharmaceutical Compositions

The peptidases of the present treatment methods may be incorporated into pharmacologically active compositions made in accordance with methods that are standard in the art (see *e.g.*, Remington's Pharmaceutical Sciences, 16<sup>th</sup> ed., A. Oslo Editor, Easton PA (1980)). Peptidases will typically be prepared in admixture with conventional excipients. Suitable carriers include, but are not limited to: water; salt solutions; alcohols; gum arabic; vegetable oils; benzyl alcohols; polyethylene glycols; gelatin; carbohydrates such as lactose, amylose or starch; magnesium stearate; talc; silicic acid; viscous paraffin; perfume oil; fatty acid esters; hydroxymethylcellulose; polyvinyl pyrrolidone, etc. The pharmaceutical preparations can be sterilized and, if desired, mixed with auxiliary agents such as: lubricants; preservatives; stabilizers; wetting agents; emulsifiers; salts for influencing osmotic pressure; buffers; coloring agents; flavoring agents; and/or aromatic substances.

Generally, the compositions of this invention will be dispensed in a unit dosage form comprising one or more active compounds in a pharmaceutically acceptable carrier. Dosages for a given patient can be determined using methods well known in the art and will be used to determine the amount of active compound in each unit dosage form. In the case of liquid

dosage formulations, it is expected that peptidase will be present in an amount of between 1 µg/ml and 10 mg/ml and, more commonly, at a concentration of between 10 µg/ml and 1 mg/ml. Non-liquid dosage forms will typically contain peptidase in a similar range per unit dose.

5

### C. Dosage Forms and Routes of Administration

The present invention is compatible with any route of administration and any dosage form. Nevertheless, in order to avoid potential degradation of peptides in the gut of patients, parenteral delivery will generally be preferred. Apart from parenteral delivery, agents may be administered orally, topically, perorally, internally, intranasally, rectally, vaginally, lingually and transdermally. Specific dosage forms include tablets, pills, capsules, powders, aerosols, suppositories, skin patches, parenterals, sustained release preparations, and oral liquids including suspensions, solutions and emulsions. If desired, compositions may be freeze-dried and the lyophilizates used for the preparation of products for injection.

15

All dosage forms may be prepared using methods that are standard in the art (see *e.g.*, Remington's Pharmaceutical Sciences, 16<sup>th</sup> ed., A. Oslo Editor, Easton PA (1980)). Solutions can be prepared using water or physiologically compatible organic solvents such as ethanol, 1,2-propylene glycol, polyglycols, dimethyl sulfoxides, fatty alcohols, triglycerides, partial esters of glycerine and the like. Parenteral compositions may be used for intravenous, intraarterial, intramuscular, intraperitoneal, intracutaneous or subcutaneous delivery. The preparations can be made using conventional techniques and may include sterile isotonic saline, water, 1, 3-butanediol, ethanol, 1,2-propylene glycol, polyglycols mixed with water, Ringer's solution, etc.

25

### D. Treatment Methods

Although the present invention includes the treatment of a wide variety of different diseases, the therapeutic objective will always be the same. Specifically, sufficient peptidase must be delivered to a patient to reduce levels of substance P to a point where one or more symptoms associated with the disease being treated are alleviated. For example, a patient being treated for rheumatoid arthritis should receive sufficient drug to alleviate pain associated with this condition. Similarly, a patient being treated for a neurodegenerative disease or autoimmune disease should receive sufficient peptidase to slow the progression of

30

the disease or reduce one or more of its physical manifestations. The effectiveness of a particular dosage will typically be assessed by clinical examination of patients using methods well known in the art of medicine.

5 In general, a patient may receive a relatively small dose of peptidase and then administration may be repeated as necessary. For example, a patient may begin by receiving 0.1 mg per day and then increase the dosage upward using changes in symptoms as a guide. It is expected that patients will receive peptidases in unit dosage forms containing between 1  $\mu$ g and 1 mg, and typically, between 5  $\mu$ g and 500  $\mu$ g. Daily dosages may vary between 10  $\mu$ g  
10 and 50 mg and may be provided in either a single or multiple regimen with the latter being generally preferred. In addition, the patient may concurrently receive other agents supplied in the same dosage form or separately. These are simply guidelines, since the actual dose will be determined by the patient and physician based upon a variety of clinical factors.

### 15 Examples

In one set of experiments, the effect of the administration of DPP IV on bronchoconstriction evoked by histamine was studied. Changes in airway resistance in an anesthetised rabbit, either before or after the intratracheal administration of DPP IV, are shown in Figure 1. The results indicate that significantly less resistance occurred after DPP IV  
20 treatment. Since histamine acts by inducing the release of neurogenic substances, including substance P, the results are consistent with the hypothesis that DPP IV inactivates substance P.

In other experiments, histamine was administered to rabbits to induce vasodilation in  
25 the femoral artery of rabbits and vascular resistance was measured. It was found that pretreatment with intravenous DPP IV led to substantially reduced histamine activity (Figure 2). Similar results were obtained in experiments measuring vasodilation directly induced by substance P (Figure 3). These results provide support for the view that DPP IV inhibits the action of substance P and can be administered *in vivo* to attenuate its activity.

30 All references cited are fully incorporated by reference. Having now fully described the invention, it will be understood by those of skill in the art that the invention may be



performed within a wide and equivalent range of conditions, parameters and the like, without affecting the spirit or scope of the invention or any embodiment thereof.